
The drugmaker expects annual sales growth of 5% through 2031 and raised peak sales guidance for three key medicines.
Novartis expects net sales to grow at a 5% constant-currency annual rate from 2026 to 2031, and said its core operating income margin is on track to return to at least 40% by 2029.
The company raised peak sales guidance for Kesimpta to $8 billion from $6 billion. Guidance for Scemblix and Leqvio increased to $5 billion each, from $4 billion.
Novartis said it now has nine marketed medicines with peak sales potential of $3 billion to $10 billion. It also expects more than 35 potentially submission-enabling trial readouts through 2031, and said 10 late-stage pipeline assets have multi-billion-dollar peak sales guidance.
The company expects its pipeline and marketed products to support sustained mid-single-digit sales growth over the longer term. Those projections are company guidance, and Novartis noted that actual results may differ.
As of 14:24 UTC, Novartis shares traded at CHF 127.80, down 2.8% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.